TVTX

Business Context and Reporting Period

Travere Therapeutics, Inc. (TVTX) is a biopharmaceutical company focused on rare kidney and metabolic diseases. This Form 10-Q covers the quarterly period ended September 30, 2025. The company's primary commercial product is FILSPARI (sparsentan) for IgAN, which received full FDA approval in September 2024. The company also markets Thiola/Thiola EC for cystinuria and is developing sparsentan for FSGS and pegtibatinase for homocystinuria.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Total revenue increased 162% year-over-year in Q3 2025, driven by a 155% increase in net product sales (primarily FILSPARI) and a massive increase in license revenue due to milestone achievements.
• Profitability: The company reported a net income of $25.7M in Q3 2025, a significant turnaround from a net loss of $54.8M in Q3 2024. This was primarily due to $51.7M in license and collaboration revenue recognized in the quarter.
• Debt Reduction: The company repaid the remaining $68.9M principal of its 2.50% Convertible Senior Notes due 2025 upon maturity in September 2025. Total debt decreased from $379.0M at year-end 2024 to $311.4M.
• Expense Management: Research and Development (R&D) expenses remained relatively flat quarter-over-quarter ($51.9M vs $51.7M), despite a pause in the pegtibatinase Phase 3 trial, offset by increased internal personnel costs. Selling, General, and Administrative (SG&A) expenses increased 32% to $86.5M, driven by commercial investments for FILSPARI and amortization of intangible assets.

Guidance, Outlook, and Risks

• Regulatory Milestones: The FDA accepted the sNDA for FILSPARI for FSGS with a PDUFA target action date of January 13, 2026. The FDA indicated an advisory committee meeting is no longer needed.
• Clinical Updates: Enrollment in the Phase 3 HARMONY Study for pegtibatinase remains paused to address manufacturing scale-up issues, with a goal to restart in 2026.
• Commercialization: FILSPARI received standard marketing authorization in the EU in April 2025. The company recognized a $40.0M market access milestone in Q3 2025 (received in Q4) and a $17.5M regulatory milestone in May 2025.
• Strategic Transaction: In October 2025 (subsequent event), partner Renalys announced an agreement to be acquired by Chugai Pharmaceutical, granting Chugai exclusive rights to sparsentan in Japan, South Korea, and Taiwan. Travere is entitled to a portion of the upfront payment and future milestones/royalties.
• Risks: Key risks include the potential failure of the FSGS sNDA, manufacturing challenges for pegtibatinase, generic competition for Thiola, and the company's dependence on third-party manufacturers and collaborators for global commercialization.

Investor Verification Checklist

• Milestone Recognition: Verify the accounting treatment and cash receipt timing of the $57.5M in regulatory and market access milestones recognized in the first nine months of 2025.
• FSGS Approval Probability: Assess the likelihood of FDA approval for FILSPARI in FSGS by the January 2026 PDUFA date, given the previous failure to meet the primary eGFR endpoint in the DUPLEX study.
• Pegtibatinase Timeline: Confirm the timeline for restarting the HARMONY Phase 3 trial and the resolution of manufacturing scale-up issues.
• Renalys Transaction: Monitor the closing of the Chugai/Renalys transaction and the specific terms regarding Travere's minority stake and future royalty rights.
• Liquidity Runway: Evaluate the company's cash burn rate post-Q3 2025 and the sufficiency of current cash and marketable securities ($254.5M total) to fund operations through the FSGS decision and pegtibatinase restart.